All In MedTech

Device Trial Radar · NCT06445179

ENDOmetriosis Robotic Assisted Surgery

Robot-Assisted Versus Standard Laparoscopic Approach of Total Hysterectomy for Deep Infiltrating Endometriosis and Adenomyosis: A Multicenter, Open-label Randomized Controlled Trial

Last checked: Nov 20, 2026Latest source record: Jan 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 224 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

224

Planned (sponsor's estimate)

Start

Apr 16, 2025

Primary completion

Jun 2027

Study completion Jun 2027

Sponsor

Lead sponsor
GCS Ramsay Santé pour l'Enseignement et la RechercheAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Euraxi Pharma
First posted
Jun 6, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the robot-assisted approach with the laparoscopic approach in terms of reducing the rates of intraoperative and postoperative complications in patients undergoing total hysterectomy for DIE and adenomyosis without digestive tract involvement.

Conditions

  • Endometriosis

Interventions

  • Total Laparoscopic HysterectomyProcedure

    The standard procedure for performing total hysterectomy will also follow the Querleu and Morrow classification system, which divides the procedure into four types based on the extent of resection: * Type A: minimum resection of paracervix. * Type B: transection of the paracervix and the ureter. * Type C: Transection of paracervix at the junction with the internal iliac vascular system * Type D: Laterally extended resection. Furthermore, bilateral ureterolysis will be performed with the option of bilateral concomitant salpingo-oophorectomy.

  • UreterolysisDevice

    unilateral or bilateral ureterolysis with or without bilateral adnexectomy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Intra and post-operative complication ratesTime frame: 3 months

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital Privé de Provence

    Aix-en-Provence, France · Recruiting

  • Hôpital Privé le Bois

    Lille, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.